Eosinophilic bioactivities in severe asthma

Tara F. Carr, Sergejs Berdnikovs, Hans Uwe Simon, Bruce S. Bochner, Lanny J. Rosenwasser*

*Corresponding author for this work

Research output: Contribution to journalReview article

31 Scopus citations

Abstract

Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through the production and release of diverse chemokines, cytokines, lipid mediators and other growth factors. Eosinophils may persist in the blood and airways despite guidelines-based treatment. This review details eosinophil effector mechanisms, surface markers, and clinical outcomes associated with eosinophilia and asthma severity. There is interest in the potential of eosinophils or their products to predict treatment response with biotherapeutics and their usefulness as biomarkers. This is important as monoclonal antibodies are targeting cytokines and eosinophils in different lung environments for treating severe asthma. Identifying disease state-specific eosinophil biomarkers would help to refine these strategies and choose likely responders to biotherapeutics.

Original languageEnglish (US)
Article number112
JournalWorld Allergy Organization Journal
Volume9
Issue number1
DOIs
StatePublished - Jun 27 2016

    Fingerprint

Keywords

  • Bioactivities
  • Biotherapeutics
  • Eosinophilia
  • Eosinophils
  • Severe asthma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Cite this